ACST Acasti Pharma Inc.Stock Price & Overview
$2.16-0.01 (-0.46%)3:59 PM 12/01/23
NASDAQ | $USD | Post-Market: $2.16 6:53 PM
People Also Follow
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.